Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: A nebulized respiratory therapy setup illustrates the clinical focus behind AeroRx Therapeutics’ AERO-007 Phase 2a COPD data, as researchers evaluate whether once-daily LABA+LAMA nebulized treatment can address persistent delivery challenges in chronic obstructive pulmonary disease care.
Pharma & Biotech

Can AeroRx turn nebulized COPD treatment into a first-line dual bronchodilator category?

COPD care relies on handheld inhalers, but many patients struggle with delivery. AeroRx is testing whether nebulized dual therapy can close that gap.

Read More
Representative image: Clinicians reviewing lung cancer imaging and genomic test results, reflecting Bayer’s HYRNUO FDA Priority Review and the growing role of precision oncology in HER2-mutated non-small cell lung cancer treatment.
Pharma & Biotech

Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing

Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.

Read More
Representative image of neonatal gene therapy research in a modern clinical setting. iECURE’s ECUR-506 data have sharpened interest in whether targeted gene insertion could reduce hyperammonemic events in infants with neonatal-onset OTC deficiency.
Pharma & Biotech

Is iECURE’s infant gene editing therapy quietly changing the OTC deficiency playbook?

A rare disease gene editing signal is only the start. iECURE now has to prove ECUR-506 can sustain OTC deficiency control.

Read More
Representative image: A bronchoscopy procedure room illustrates how Fujifilm’s EB-710US balloon-less EBUS bronchoscope could support more efficient pulmonary imaging, lung cancer diagnosis, and minimally invasive endobronchial ultrasound workflows.
Medical Devices & Diagnostics

Can Fujifilm’s EB-710US simplify lung cancer staging procedures in the United States?

EBUS imaging is clinically valuable, but workflow remains messy. Fujifilm’s EB-710US tests whether simpler design can change adoption.

Read More
Representative image: Scientists analyze CRISPR gene-editing and liver-targeted cardiometabolic research data in a biotech laboratory, reflecting Scribe Therapeutics’ push to advance epigenetic silencing for durable LDL-C reduction.
Pharma & Biotech

Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs

CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.

Read More
Representative image of a urologist discussing overactive bladder and benign prostatic hyperplasia treatment data with an older male patient, reflecting Sumitomo Pharma America’s AUA 2026 vibegron findings in men aged 75 and older.
Pharma & Biotech

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.

Read More
Representative image of a modern bioanalytical laboratory, highlighting how Thermo Fisher Scientific’s PPD Clinical Research expansion in Gothenburg strengthens biomarker testing and complex drug development support for pharmaceutical and biotechnology companies.
Pharma & Biotech

Why Thermo Fisher’s new Gothenburg lab matters for the next phase of complex drug development

Complex therapies need deeper trial data. Thermo Fisher’s Gothenburg lab shows why bioanalysis is becoming a CRO battleground.

Read More
Representative image of a clinical diagnostics lab reviewing blood-based MRD test results, as Veracyte’s TrueMRD Medicare coverage decision pushes whole-genome bladder cancer recurrence monitoring closer to routine oncology care.
Medical Devices & Diagnostics

Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance

MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.

Read More
Representative image: A home health clinician speaks with an elderly couple during an in-home care consultation, reflecting Enhabit’s move into private ownership under Kinderhook Industries as the home health and hospice sector faces rising demand, tighter margins, and renewed private equity interest.
Pharma & Biotech

Why Kinderhook’s Enhabit acquisition could reset the home health and hospice playbook

Home care demand is rising, but margins remain tight. Enhabit’s Kinderhook exit tests whether private equity can unlock scale without care risk.

Read More
Representative image: A clinical research laboratory setting illustrates Meiji Seika Pharma’s nacubactam Phase III progress, as the novel β-lactamase inhibitor advances the fight against complicated urinary tract infections, acute pyelonephritis and antimicrobial resistance.
Pharma & Biotech

Nacubactam trial win gives Meiji Seika Pharma a stronger AMR case, but approval hurdles remain

Antibiotic resistance needs new tools. Meiji Seika Pharma’s nacubactam now has Phase III data, but regulators must judge its real-world fit.

Read More